Gelteq (GELS) Competitors

$0.42 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$0.42 +0.00 (+0.71%)

As of 05/22/2026 04:02 PM Eastern

GELS vs. QNCX, ANEB, LPCN, NCEL, and AEON

Should you buy Gelteq stock or one of its competitors? MarketBeat compares Gelteq with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gelteq include Quince Therapeutics (QNCX), Anebulo Pharmaceuticals (ANEB), Lipocine (LPCN), NLS Pharmaceutics (NCEL), and AEON Biopharma (AEON). These companies are all part of the "pharmaceutical products" industry.

How does Gelteq compare to Quince Therapeutics?

Gelteq (NASDAQ:GELS) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Gelteq has higher revenue and earnings than Quince Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	41.09	-$4.30M	N/A	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A

Gelteq has a beta of 0.06, meaning that its share price is 94% less volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

In the previous week, Gelteq had 2 more articles in the media than Quince Therapeutics. MarketBeat recorded 3 mentions for Gelteq and 1 mentions for Quince Therapeutics. Gelteq's average media sentiment score of 0.13 beat Quince Therapeutics' score of 0.08 indicating that Gelteq is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gelteq	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quince Therapeutics has a consensus price target of $65.00, indicating a potential upside of 5,809.09%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

30.8% of Quince Therapeutics shares are held by institutional investors. 20.3% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Gelteq's return on equity of 0.00% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Quince Therapeutics	N/A	-372.88%	-67.99%

Summary

Gelteq beats Quince Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Gelteq compare to Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Anebulo Pharmaceuticals has a beta of -1.93, suggesting that its share price is 293% less volatile than the broader market. Comparatively, Gelteq has a beta of 0.06, suggesting that its share price is 94% less volatile than the broader market.

28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Gelteq's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Gelteq	N/A	N/A	N/A

Gelteq has higher revenue and earnings than Anebulo Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
Gelteq	$110K	41.09	-$4.30M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Gelteq had 2 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 3 mentions for Gelteq and 1 mentions for Anebulo Pharmaceuticals. Gelteq's average media sentiment score of 0.13 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Gelteq is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anebulo Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gelteq	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Gelteq beats Anebulo Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

How does Gelteq compare to Lipocine?

Gelteq (NASDAQ:GELS) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

9.1% of Lipocine shares are owned by institutional investors. 6.4% of Lipocine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Gelteq had 3 more articles in the media than Lipocine. MarketBeat recorded 3 mentions for Gelteq and 0 mentions for Lipocine. Gelteq's average media sentiment score of 0.13 beat Lipocine's score of 0.00 indicating that Gelteq is being referred to more favorably in the media.

Company	Overall Sentiment
Gelteq	Neutral
Lipocine	Neutral

Gelteq has higher earnings, but lower revenue than Lipocine.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	41.09	-$4.30M	N/A	N/A
Lipocine	$1.98M	9.41	-$9.63M	-$1.88	N/A

Lipocine has a consensus price target of $15.00, indicating a potential upside of 563.72%. Given Lipocine's stronger consensus rating and higher possible upside, analysts clearly believe Lipocine is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Gelteq has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Gelteq's return on equity of 0.00% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Lipocine	-571.18%	-66.70%	-59.39%

Gelteq has a beta of 0.06, indicating that its share price is 94% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

Summary

Gelteq and Lipocine tied by winning 7 of the 14 factors compared between the two stocks.

How does Gelteq compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

In the previous week, Gelteq had 3 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 3 mentions for Gelteq and 0 mentions for NLS Pharmaceutics. Gelteq's average media sentiment score of 0.13 beat NLS Pharmaceutics' score of 0.00 indicating that Gelteq is being referred to more favorably in the news media.

Company	Overall Sentiment
NLS Pharmaceutics	Neutral
Gelteq	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NLS Pharmaceutics has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Comparatively, Gelteq has a beta of 0.06, meaning that its share price is 94% less volatile than the broader market.

Gelteq has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Gelteq	$110K	41.09	-$4.30M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Gelteq	N/A	N/A	N/A

Summary

Gelteq beats NLS Pharmaceutics on 4 of the 5 factors compared between the two stocks.

How does Gelteq compare to AEON Biopharma?

AEON Biopharma (NASDAQ:AEON) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Gelteq	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Gelteq had 3 more articles in the media than AEON Biopharma. MarketBeat recorded 3 mentions for Gelteq and 0 mentions for AEON Biopharma. Gelteq's average media sentiment score of 0.13 beat AEON Biopharma's score of 0.00 indicating that Gelteq is being referred to more favorably in the news media.

Company	Overall Sentiment
AEON Biopharma	Neutral
Gelteq	Neutral

22.8% of AEON Biopharma shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Gelteq has higher revenue and earnings than AEON Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$5.00	N/A
Gelteq	$110K	41.09	-$4.30M	N/A	N/A

AEON Biopharma has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Gelteq has a beta of 0.06, meaning that its stock price is 94% less volatile than the broader market.

Summary

AEON Biopharma beats Gelteq on 6 of the 11 factors compared between the two stocks.

Get Gelteq News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GELS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GELS vs. The Competition

Export

Metric	Gelteq	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.52M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	N/A	18.74	20.99	25.66
Price / Sales	41.09	323.98	559.58	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	0.39	7.09	10.44	7.14
Net Income	-$4.30M	$24.45M	$3.57B	$335.98M
7 Day Performance	8.18%	6.38%	6.37%	4.11%
1 Month Performance	-39.67%	2.43%	3.51%	2.52%
1 Year Performance	-76.56%	62.98%	34.10%	35.04%

Gelteq Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GELS Gelteq	1.2784 of 5 stars	$0.42 flat	N/A	-76.6%	$4.52M	$110K	N/A	N/A
QNCX Quince Therapeutics	2.1439 of 5 stars	$1.15 -2.5%	$65.00 +5,552.2%	-90.1%	$19.24M	N/A	N/A	60	Gap Down
ANEB Anebulo Pharmaceuticals	0.0325 of 5 stars	$0.46 -11.5%	N/A	-58.9%	$18.76M	N/A	N/A	4	Gap Up
LPCN Lipocine	2.9104 of 5 stars	$2.26 -3.0%	$15.00 +563.7%	-36.9%	$18.63M	$2.00M	N/A	10
NCEL NLS Pharmaceutics	0.7241 of 5 stars	$3.21 -6.4%	N/A	-82.9%	$18.33M	N/A	N/A	6	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GELS) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gelteq (GELS) Competitors

GELS vs. QNCX, ANEB, LPCN, NCEL, and AEON

How does Gelteq compare to Quince Therapeutics?

Summary

How does Gelteq compare to Anebulo Pharmaceuticals?

Summary

How does Gelteq compare to Lipocine?

Summary

How does Gelteq compare to NLS Pharmaceutics?

Summary

How does Gelteq compare to AEON Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS vs. The Competition

Gelteq Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gelteq (GELS) Competitors

GELS vs. QNCX, ANEB, LPCN, NCEL, and AEON

How does Gelteq compare to Quince Therapeutics?

Which has preferable valuation & earnings, GELS or QNCX?

Which has more volatility & risk, GELS or QNCX?

Does the media prefer GELS or QNCX?

Do analysts recommend GELS or QNCX?

Do institutionals and insiders believe in GELS or QNCX?

Is GELS or QNCX more profitable?

Summary

How does Gelteq compare to Anebulo Pharmaceuticals?

Which has more risk and volatility, ANEB or GELS?

Do insiders & institutionals have more ownership in ANEB or GELS?

Is ANEB or GELS more profitable?

Which has higher valuation & earnings, ANEB or GELS?

Do analysts prefer ANEB or GELS?

Does the media favor ANEB or GELS?

Summary

How does Gelteq compare to Lipocine?

Do insiders and institutionals believe in GELS or LPCN?

Does the media prefer GELS or LPCN?

Which has higher earnings and valuation, GELS or LPCN?

Do analysts rate GELS or LPCN?

Is GELS or LPCN more profitable?

Which has more volatility and risk, GELS or LPCN?

Summary

How does Gelteq compare to NLS Pharmaceutics?

Does the media favor NCEL or GELS?

Do analysts rate NCEL or GELS?

Which has more risk & volatility, NCEL or GELS?

Which has preferable valuation and earnings, NCEL or GELS?

Is NCEL or GELS more profitable?

Summary

How does Gelteq compare to AEON Biopharma?

Is AEON or GELS more profitable?

Do analysts recommend AEON or GELS?

Does the media favor AEON or GELS?

Do institutionals and insiders believe in AEON or GELS?

Which has better earnings and valuation, AEON or GELS?

Which has more risk & volatility, AEON or GELS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS vs. The Competition

Gelteq Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools